6533b861fe1ef96bd12c4621

RESEARCH PRODUCT

Pathophysiology of anthracycline cardiotoxicity.

Paolo SpallarossaConcetta ZitoPasquale PagliaroDonato MeleAlessia PepeRosalinda MadonnaCarlo G. TocchettiNicola MaureaGiuseppina Novo

subject

DrugAnthracyclinemedia_common.quotation_subjectLeftanthracyclines; cancer; cardiotoxicity; Cardiology and Cardiovascular MedicineDose dependenceAntineoplastic Agents030204 cardiovascular system & hematologyanthracyclineBioinformatics03 medical and health sciencesVentricular Dysfunction Left0302 clinical medicineAntibioticsNeoplasmsVentricular DysfunctionmedicinecancerHumansGenetic Predisposition to DiseaseAnthracyclinesmedia_commonHeart FailureCardiotoxicityAntibiotics AntineoplasticDose-Response Relationship Drugbusiness.industryanthracyclines cancer cardiotoxicityCancerHeartGeneral Medicinebiochemical phenomena metabolism and nutritionmedicine.diseaseAntineoplasticPathophysiologyCardiotoxicityCardiovascular Diseases030220 oncology & carcinogenesisHeart failureCardiology and Cardiovascular Medicinebusinessanthracyclines; cancer; cardiotoxicity; Anthracyclines; Antibiotics Antineoplastic; Cardiotoxicity; Heart Failure; Humans; Neoplasms; Ventricular Dysfunction Left

description

Anthracyclines (ANTs) are powerful drugs that have reduced the mortality of cancer patients. However, their use is limited by the development of cardiotoxicity (CTX), which is dose dependent and may lead to left ventricular dysfunction and heart failure. Although various strategies have been suggested to reduce the negative effects of ANTs, CTX is still an important unresolved clinical issue. This may be due at least partly to the incomplete characterization of the molecular and cellular mechanisms of ANT-induced CTX. In addition, although various forms of cardiac damage have been demonstrated with the use of these drugs in experimental studies, it is not yet clear how these translate to the clinical setting. Appropriate characterization of potential candidates for ANT-based therapies is essential to decide whether to administer these drugs. Hopefully, new information from genetic profiling will help to identify patients who are at high risk of developing CTX.

yearjournalcountryeditionlanguage
2016-01-01Journal of cardiovascular medicine (Hagerstown, Md.)
10.2459/jcm.0000000000000378https://pubmed.ncbi.nlm.nih.gov/27755237